SK3442002A3 - Formulations for parenteral use of estramustine phosphate and amino acids - Google Patents

Formulations for parenteral use of estramustine phosphate and amino acids Download PDF

Info

Publication number
SK3442002A3
SK3442002A3 SK344-2002A SK3442002A SK3442002A3 SK 3442002 A3 SK3442002 A3 SK 3442002A3 SK 3442002 A SK3442002 A SK 3442002A SK 3442002 A3 SK3442002 A3 SK 3442002A3
Authority
SK
Slovakia
Prior art keywords
estramustine phosphate
pharmaceutical composition
arginine
composition according
cancer
Prior art date
Application number
SK344-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Lorena Muggetti
Paolo Colombo
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of SK3442002A3 publication Critical patent/SK3442002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK344-2002A 1999-09-16 2000-09-13 Formulations for parenteral use of estramustine phosphate and amino acids SK3442002A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921960.2A GB9921960D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate and amino acids
PCT/EP2000/008983 WO2001019372A1 (en) 1999-09-16 2000-09-13 Formulations for parenteral use of estramustine phosphate and amino acids

Publications (1)

Publication Number Publication Date
SK3442002A3 true SK3442002A3 (en) 2002-09-10

Family

ID=10861070

Family Applications (1)

Application Number Title Priority Date Filing Date
SK344-2002A SK3442002A3 (en) 1999-09-16 2000-09-13 Formulations for parenteral use of estramustine phosphate and amino acids

Country Status (22)

Country Link
EP (1) EP1214078B1 (de)
JP (1) JP2003509372A (de)
KR (1) KR20020059592A (de)
CN (1) CN1373667A (de)
AT (1) ATE283053T1 (de)
AU (1) AU779922B2 (de)
BR (1) BR0014071A (de)
CA (1) CA2384726A1 (de)
CZ (1) CZ2002945A3 (de)
DE (1) DE60016252D1 (de)
EA (1) EA005311B1 (de)
GB (1) GB9921960D0 (de)
HK (1) HK1048948A1 (de)
HU (1) HUP0202729A3 (de)
IL (1) IL148513A0 (de)
MX (1) MXPA02002854A (de)
NO (1) NO20021302L (de)
NZ (1) NZ518182A (de)
PL (1) PL354746A1 (de)
SK (1) SK3442002A3 (de)
WO (1) WO2001019372A1 (de)
ZA (1) ZA200202689B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318689B1 (it) * 2000-09-12 2003-08-27 Pharmacia & Upjohn Spa Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
MX2007015949A (es) 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
GB2471065A (en) * 2009-06-10 2010-12-22 Univ Sheffield Modulator of claspin for treatment of cell proliferative disorder
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP5806287B2 (ja) 2010-03-30 2015-11-10 フォスファジェニクス リミティド 経皮送達パッチ
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
EP3265059A4 (de) 2015-03-03 2018-08-29 Cureport Inc. Liposomale pharmazeutische kombinationsformulierungen
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
WO2024102547A1 (en) * 2022-11-11 2024-05-16 Michael Farber Anhydrous compositions of polysorbates and cyclodextrins for shelf stable drug combinations with macrocyclic lactone complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807572A (en) * 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

Also Published As

Publication number Publication date
HK1048948A1 (zh) 2003-04-25
NO20021302L (no) 2002-04-24
HUP0202729A2 (hu) 2003-01-28
AU7776200A (en) 2001-04-17
EA200200368A1 (ru) 2002-10-31
MXPA02002854A (es) 2003-07-21
NO20021302D0 (no) 2002-03-15
DE60016252D1 (de) 2004-12-30
BR0014071A (pt) 2002-05-21
CN1373667A (zh) 2002-10-09
CZ2002945A3 (cs) 2002-07-17
ATE283053T1 (de) 2004-12-15
EP1214078B1 (de) 2004-11-24
NZ518182A (en) 2004-02-27
JP2003509372A (ja) 2003-03-11
AU779922B2 (en) 2005-02-17
EP1214078A1 (de) 2002-06-19
IL148513A0 (en) 2002-09-12
EA005311B1 (ru) 2004-12-30
KR20020059592A (ko) 2002-07-13
HUP0202729A3 (en) 2003-12-29
PL354746A1 (en) 2004-02-23
CA2384726A1 (en) 2001-03-22
WO2001019372A1 (en) 2001-03-22
ZA200202689B (en) 2003-10-29
GB9921960D0 (en) 1999-11-17

Similar Documents

Publication Publication Date Title
EP1214078B1 (de) Parenteral anzuwendende arzneizusammensetzungen enthaltend estramustinphosphat und aminosäure
US6730664B1 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
SK1782002A3 (en) Formulations for parenteral use of estramustine phosphate and albumin
SK3452002A3 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
JP2004508406A (ja) 薬剤の静脈内投与に伴う副作用を予防および治療するための薬物の調製におけるアルギニンの使用
HK1063153A (en) Formulations for parenteral use of estramustine phosphate and albumin
ZA200201955B (en) Formulations for parenteral use of estramustine phosphate and albumin.
ITMI991998A1 (it) Formulazioni di estramustina fosfato ed albumina per uso parenterale